Triomics Analysis: $15M Raised
What is Triomics?
Triomics leverages generative AI to enhance oncology research and care by accelerating trial enrollment, improving quality, and streamlining healthcare operations.
Employees
50
Founded
2021
Revenue
$9.3-10.5M
Product Features & Capabilities
- Trial Enrollment, Patient-to-Trial Matching, Clinical Navigators, Quality Improvement, Care Operations, Triaging, Scheduling and Pre-Charting
Pricing
- Pricing is based on a subscription model.
- Detailed pricing plans are not publicly available.
- Custom solutions are offered, with pricing varying based on scale and customization.
- Interested parties should contact Triomics directly for specific pricing information.
How much Triomics raised
Series A - $15 million
May 9, 2024Lead Investor: Lightspeed Venture Partners, Nexus Venture Partners, and others.
Who are the founders of Triomics
Market Focus
Triomics primarily focuses on the healthcare industry, specifically in oncology research and care operations, utilizing generative AI to enhance trial enrollment and streamline healthcare processes.
Investors
- Lightspeed Venture Partners
- General Catalyst
- Nexus Venture Partners
- Y Combinator
Competitors Overview
Triomics operates in the oncology research and healthcare technology market, focusing on enhancing trial enrollment and streamlining operations through generative AI. Its main competitors include:
- Vim: Known for its configurable text editing capabilities, Vim enhances patient acquisition and
Business Model
Partners with healthcare providers, leveraging AI for workflow optimization and revenue sharing.
See something that needs updating? Suggest edits to this profile.